Show simple item record

2022-07-09Zeitschriftenartikel
Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany
dc.contributor.authorNygren, Teresa M.
dc.contributor.authorPilic, Antonia
dc.contributor.authorBöhmer, Merle M.
dc.contributor.authorWagner-Wiening, Christiane
dc.contributor.authorWichmann, Ole
dc.contributor.authorHarder, Thomas
dc.contributor.authorHellenbrand, Wiebke
dc.date.accessioned2024-08-29T07:36:46Z
dc.date.available2024-08-29T07:36:46Z
dc.date.issued2022-07-09none
dc.identifier.other10.1038/s41598-022-15447-5
dc.identifier.urihttp://edoc.rki.de/176904/12018
dc.description.abstractTick-borne encephalitis (TBE) vaccination coverage remains low in Germany. Our case–control study (2018–2020) aimed to examine reasons for low vaccine uptake, vaccine effectiveness (VE), and vaccine breakthrough infections (VBIs). Telephone interviews (581 cases, 975 matched controls) covered vaccinations, vaccination barriers, and confounders identified with directed acyclic graphs. Multivariable logistic regression determined VE as 1—odds ratio with 95% confidence intervals (CI). We additionally calculated VE with the Screening method using routine surveillance and vaccination coverage data. Main vaccination barriers were poor risk perception and fear of adverse events. VE was 96.6% (95% CI 93.7–98.2) for ≥ 3 doses and manufacturer-recommended dosing intervals. Without boosters, VE after ≥ 3 doses at ≤ 10 years was 91.2% (95% CI 82.7–95.6). VE was similar for homologous/heterologous vaccination. Utilising routine surveillance data, VE was comparable (≥ 3 doses: 92.8%). VBIs (n = 17, 2.9% of cases) were older, had more comorbidities and higher severity than unvaccinated cases. However, only few VBIs were diagnostically confirmed; 57% of re-tested vaccinated cases (≥ 1 dose, n = 54) proved false positive. To increase TBE vaccine uptake, communication efforts should address complacency and increase confidence in the vaccines’ safety. The observed duration of high VE may inform decision-makers to consider extending booster intervals to 10 years.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleTick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germanynone
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/12018-6
dc.type.versionpublishedVersionnone
local.edoc.container-titlescientific reportsnone
local.edoc.container-issn2045-2322none
local.edoc.pages10none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.nature.com/srep/none
local.edoc.container-publisher-nameSpringer Naturenone
local.edoc.container-volume12none
local.edoc.container-reportyear2022none
dc.description.versionPeer Reviewednone

Show simple item record